menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1||Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1||Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1||Sphingosine 1-phosphate receptor Edg-1","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Priothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Undisclosed"},{"orgOrder":0,"company":"Priothera","sponsor":"Fountain Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Series A financing","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Fountain Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Fountain Healthcare"},{"orgOrder":0,"company":"Priothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Undisclosed"},{"orgOrder":0,"company":"Priothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Undisclosed"},{"orgOrder":0,"company":"EUROAPI","sponsor":"Priothera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"EUROAPI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EUROAPI \/ Priothera","highestDevelopmentStatusID":"10","companyTruncated":"EUROAPI \/ Priothera"},{"orgOrder":0,"company":"Priothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Undisclosed"},{"orgOrder":0,"company":"Priothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Undisclosed"},{"orgOrder":0,"company":"Priothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Undisclosed"},{"orgOrder":0,"company":"Priothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mocravimod","moa":"||S1PR1","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priothera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Mocravimod

    Menu

    Mocravimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EUROAPI

                            France
                            DDL Conference
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Priothera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EUROAPI and Priothera enter into CDMO collaboration to advance oncology project

                            Details : The collaboration aims to support Protheria for the development and manufacturing KRP203 (mocravimod), which is being evaluated in the late-stage for the treatment of adult acute myeloid leukemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 18, 2024

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Priothera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            EUROAPI Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Priothera “ US FDA grants Orphan Drug Designation to Mocravimod to Improve the Outcome of Allogeneic Hematop...

                            Details : Mocravimod, a sphingosine-1-phosphate (S1P) receptor modulator, is being investigated in a pivotal global Phase 3 study 'treatment of acute myeloid leukemia (AML).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2023

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Priothera Cleared to Begin Japanese Arm of Pivotal Phase 3 Study with Mocravimod in Patients with Acute Myeloi...

                            Details : KRP203 (mocravimod) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It is currently in phase 3 study for acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 27, 2023

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Priothera Announces First Patients Enrolled in Pivotal MO-TRANS gLobal Phase 2b/3 Study with Mocravimod as An ...

                            Details : KRP203 (mocravimod) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This drug is in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications such as AML patients undergoing HCT.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2023

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

                            Details : Mocravimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2022

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Priothera Receives Fast Track Designation for Mocravimod in Combination with Allogeneic Hematopoietic Stem Cel...

                            Details : Mocravimod (also known as KRP203), is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This novel investigational drug has been assessed in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmu...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : Mocravimod,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b/3 study with mocravimod i...

                            Details : Global Phase 2b/3 trial (MO-TRANS) assessing the efficacy and safety of mocravimod, a novel S1P receptor modulator, as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HSCT, planned to start in H2 2022.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 26, 2022

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Priothera - FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemi...

                            Details : KRP203 (mocravimod), a novel, synthetic, sphingosine 1-phosphate receptor modulator developed as a potential best-in-class adjunctive and maintenance therapy to enhance the curative potential of HSCT for AML patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2022

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Priothera

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Fountain Healthcare

                            Deal Size : $35.4 million

                            Deal Type : Series A financing

                            DEALS_DEV arrow-down

                            Priothera Closes €30 Million Series A Financing to Develop Highly Promising Therapies for Acute Myeloid Leuk...

                            Details : Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogenic hematopoietic stem cell transplantation (HSCT) for treating AML.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 12, 2020

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Fountain Healthcare

                            Deal Size : $35.4 million

                            Deal Type : Series A financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Un...

                            Details : KRP203 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2013

                            Lead Product(s) : Mocravimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth